Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

CAP TODAY

Werfen companies now under one name, brand

August 2021—Werfen announced that its companies, including Instrumentation Laboratory, Inova Diagnostics, and Biokit, are uniting under one name and one brand—Werfen—and a new corporate logo.

Cobas SARS-CoV-2 Test authorized for asymptomatic people

August 2021—Roche’s Cobas SARS-CoV-2 has received FDA emergency use authorization for testing individuals without symptoms or reasons to suspect COVID-19. This authorization supports the guidance update from the CDC to expand SARS-CoV-2 testing to include people without symptoms and applies to pooled samples containing up to and including six individual samples. Asymptomatic testing with the Cobas SARS-CoV-2 test is also available in countries accepting the CE mark.

LGC SeraCare blood TMB reference standards

August 2021—LGC SeraCare released two new blood tumor mutational burden reference standards, Seraseq Blood TMB Score 7 and Seraseq Blood TMB Score 26. The products complement the company’s Seraseq I-O portfolio of tissue-derived Seraseq gDNA TMB Score 7 and Score 26 and Seraseq FFPE TMB Score 7 and Score 26 products.

Reference materials for bilirubin, cholesterol, uric acid

August 2021—Verichem Laboratories offers liquid-stable, protein-based clinical reference materials for total and direct bilirubin assays. The Bilirubin Standard Kit, Tru-Zero Bilirubin Standard, and extended-range Level F Bilirubin Standard are intended for CLIA calibration verification with wet chemistry testing systems. Verichem’s BR2 Bilirubin Calibrator is available for use exclusively with the BR2 Bilirubin Stat Analyzer from Advanced Instruments.

Qiagen launches CE-marked Artus Prep&Amp

August 2021—Qiagen launched its Artus SARS-CoV-2 Prep&Amp UM Kit, which integrates a liquid-based sample preparation technology for COVID-19 testing that takes two minutes or less with the provided real-time PCR assay. The kit uses common transport media as the starting material and provides all reagents required for sample to result on suspected SARS-CoV-2 patient samples. The workflow can support up to 672 samples per cycler in an eight-hour shift.

FDA clears GSD’s B. burgdorferi VlsE-OspC IgG/IgM assay

August 2021—Gold Standard Diagnostics announced the availability of its FDA-cleared B. burgdorferi VlsE-OspC IgG/IgM recombinant ELISA screen. The OspC antigen is highly specific for the detection of IgM antibodies and produces a superior first-tier screen, the company says, when used in combination with the recombinant VlsE. True Lyme-negative samples are eliminated prior to second-tier testing.

Sarstedt BL 1200 Sort Connect

August 2021—Sarstedt introduced its BL 1200 Sort Connect, a preanalytical accessioning and sorting instrument that can be connected to integrated systems or analyzer lines. The unit features a bulk loader that requires no sorting or handling. Multiple tube sizes are accepted and barcodes are identified via the ID module.

From the President’s Desk: A step forward

August 2021—No doubt about it, in-person meetings are coming back. I went from a record-long stretch at home because of the pandemic to attending events all over the country. I hasten to add that my entire family is fully vaccinated, and we were so at our first opportunity. As I write this in July, I just returned from an in-person professional development meeting, and I am reminded that virtual meetings are nowhere near as effective as face-to-face meetings. That’s why I am pleased that CAP21 will be a hybrid meeting this year. It’s a step back to normal and will allow people to engage in the way that’s most comfortable for them as the COVID-19 pandemic continues in our country. It feels good to have the opportunity to come back together. I think one of the many reasons our country is so divided now is that we have been separated from each other for so long. At a recent CAP meeting I attended, there was a disagreement during one particular session. After it ended, everyone involved got together face to face, talked through the issue, and came to a good resolution.

Anatomic pathology selected abstracts

August 2021—Pseudocarcinomatous squamous hyperplasia within the bone is uncommon and closely mimics well-differentiated squamous cell carcinoma. It arises from cutaneous or mucosal surfaces and grows directly into the bone. The authors conducted a study in which they analyzed a series of 31 pseudocarcinomatous squamous hyperplasia (PSH) cases and discussed the clinicopathologic features that distinguished PSH from squamous cell carcinoma (SCC).